Salute e Benessere

Physical Therapy Supplies Market Poised for USD 27.1 Billion by 2034, Driven by…

Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-2241 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-2241 Physical therapy equipment is used to enhance mobility, build strength, support healing, and preserve general health through various means. Having personal equipment during physical therapy provides patients with...
PR Newswire
13/06/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of May 31, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (June 13, 2024 - 6:00 pm)– As of May 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down...
Nasdaq GlobeNewswire
13/06/2024

Osteotec announces strategic collaboration with Additive Surgical, bringing…

Established in 2020, Additive Surgical is the first company in Australia to offer off-the-shelf 3D-printed titanium spinal implants. After years of research and development the portfolio features proprietary PorOssity™ technology, featuring intricate biomimetic lattices and targeted porosity that promote bone growth—capabilities previously unattainable through traditional manufacturing methods. Established in 2020, Additive Surgical is the first company inAustraliato offer off-the-shelf...
PR Newswire
13/06/2024

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Company announcement – No. 31 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 13, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 2,750 divided into 2,750 new shares with a nominal value of DKK 1 each...
Nasdaq GlobeNewswire
13/06/2024

Annual general meeting has been held in SciBase Holding AB (publ)

Information regarding the newly elected board members' education, experience, assignments and independence can be found on the Company's website https://investors.scibase.se/en/governance/annual-general-meeting. Information regarding the newly elected board members' education, experience, assignments and independence can be found on the Company's websitehttps://investors.scibase.se/en/governance/annual-general-meeting. For more information, please contact: Pia Renaudin, CEO SciBase...
PR Newswire
13/06/2024

Body Composition Analyzers Market: USD 1.2B by 2029, 9.3% CAGR Boosted by Health…

Browse in-depth TOC on "Body Composition Analyzers Market" Browse in-depth TOC on "Body Composition Analyzers Market" 366 - Tables 42 - Figures 294 - Pages Driving Force: Rising Prevalence of Obesity-Related Disorders The escalating rates of obesity and associated metabolic disorders are propelling the demand for body composition analyzers. These devices offer detailed insights crucial for diagnosing and managing conditions like diabetes and cardiovascular diseases...
PR Newswire
13/06/2024

Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Mesalazine is a medication used to treat Inflammatory Bowel Diseases (IBD) such as ulcerative colitis and Crohn's disease. Mesalazine is a medication used to treat Inflammatory Bowel Diseases (IBD) such as ulcerative colitis and Crohn's disease. Since 1997, Ethypharm has pioneered the Chinese Mesalazine oral market with Etiasa®, achieving approximately 30% market share. Chinais the third-largest market of Mesalazine globally, with mainly oral forms and topical forms accounting for 20%...
PR Newswire
13/06/2024

Livestock Diagnostics Market to be Worth $2.56 billion in 2031- Exclusive Report…

Livestock diagnostics play an important role in monitoring the health status of livestock animals and identifying pathogens. It is also used for the early detection, management, and control of livestock diseases, including zoonosis. This process further facilitates the safe trade of animals and animal-derived products. Thus, livestock diagnosis has emerged as an essential part of animal disease management and prevention. Livestock diagnostics play an important role in monitoring the health...
PR Newswire
13/06/2024

SKAN Research Trust and Quadram Institute Bioscience to Develop Novel Microbial…

The joint study titled the Application of TraDIS-Xpress in Microbiology for Healthy Living will be led by Quadram Principal Investigator, Prof. Mark Webber and SKAN's Deputy Director, Dr Yogesh Shouche. The project is part of a larger Comprehensive Partnership Agreement between the two organizations that have ongoing international collaborations focused on gut health and developing gut microbial therapies to alleviate ageing and neurological diseases like Parkinsons. The joint study titled…
PR Newswire
13/06/2024

Resolution Therapeutics to Host Virtual R&D Webinar on Liver Disease with World…

The event will feature an in-depth update on the clinical data from the extended MATCH Phase 2 clinical study and provide insight on Resolution's novel discovery platform for engineered macrophage cell therapy to enhance therapeutic efficacy in end-stage liver disease (ESLD). Poster presentations on these data were presented at the EASL Congress 2024, held in Milan between 5-8 June 2024. The event will feature an in-depth update on the clinical data from the extended MATCH Phase 2 clinical...
PR Newswire
13/06/2024

SciBase strengthens the US organization with experienced leader in dermatology

Her expertise spans startup environments and the successful launches of products at renowned companies including Aventis, Amgen, Arthrex and DermTech. Leda has concentrated her efforts in the field of dermatology. Her experience in launching and driving sales of new products and technologies, building winning teams in the US dermatology market as well as experience in cost reimbursement in the US, will be key to driving SciBase US sales and market establishment forward. Her expertise spans...
PR Newswire
13/06/2024

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

As a bioequivalent version of Victoza ®pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA. The successful development of Liraglutide highlights Adalvo's capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments. Adalvo's commitment to providing access to high-quality differentiated products...
Nasdaq GlobeNewswire
13/06/2024

Idorsia holds its Annual General Meeting of Shareholders

All Board proposals approved by the shareholdersAllschwil, Switzerland – June 13, 2024At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with very large majorities.The meeting was attended by 201 shareholders, representing a total of 90,297,668 shares, or 47.78% of the total outstanding shares.Led by the Chairman of the Board, Mathieu Simon, and Jean-Paul Clozel, who...
Nasdaq GlobeNewswire
13/06/2024

Amplify Healthcare Documentation: New AI-Powered Clinical Workflow Solution…

Prescribe Digital has supported clinicians with documentation in the healthcare industry for almost 20 years. This solution comes as a new arm to their support offering, providing clinicians and administrative staff with tools to help revolutionise workflows. Prescribe Digital has supported clinicians with documentation in the healthcare industry for almost 20 years. This solution comes as a new arm to their support offering, providing clinicians and administrative staff with tools to help...
PR Newswire
13/06/2024

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for…

Xeltis' groundbreaking implants platform is an important development in vascular replacement technology as, over time, its implants are gradually replaced by the patients' own living healthy tissue. Xeltis' novel technology has already treated over 100 patients across different clinical trials. Xeltis' groundbreaking implants platform is an important development in vascular replacement technology as, over time, its implants are gradually replaced by the patients' own living healthy tissue...
PR Newswire
13/06/2024

Roborock Unveils Roborock Qrevo Master - A Powerful Self-Cleaning Robotic Vacuum…

"The Roborock Qrevo Master represents a significant leap forward in robotic cleaning technology," said Mr. Quan, Roborock President. "Offering unparalleled cleaning performance and a seamless user experience, the Roborock Qrevo Master delivers elite cleaning at an accessible price point." "The Roborock Qrevo Master represents a significant leap forward in robotic cleaning technology," saidMr. Quan, Roborock President. "Offering unparalleled cleaning performance…
PR Newswire
13/06/2024

Alta Semper acquires Allmed Group to deliver advanced blood purification and…

Alta Semper acquires Allmed Group to deliver advanced blood purification and dialysis solutions worldwide London, UK, 13 thof June 2024;Allmed Group (" Allmed " or "theCompany "), a producer of end-to-end blood purification and haemodialysis solutions, announced today that Alta Semper Capital (“ Alta Semper ”), a London-based private equity firm specialising in impact investments primarily in the healthcare sector across growth markets, has entered into definitive...
Nasdaq GlobeNewswire
13/06/2024

Adrenocortical Carcinoma Market to Exhibit Growth at a CAGR of 11.1% by 2034 |…

Key Takeaways from the Adrenocortical Carcinoma Market Report Key Takeaways from the Adrenocortical Carcinoma Market Report Discover which therapies are expected to grab the major adrenocortical carcinoma market share @Adrenocortical Carcinoma Market Report Adrenocortical Carcinoma Overview Adrenocortical carcinoma is a rare but aggressive cancer originating in the adrenal cortex. The cause of adrenocortical carcinoma is largely unknown, though genetic mutations and...
PR Newswire
12/06/2024

Aesthetic procedures close to 35 million in 2023

Aesthetic Procedures Aesthetic Procedures Liposuction was the most common surgical procedure in 2023 as in 2022, with more than 2.2 million, followed by breast augmentation, eyelid surgery, abdominoplasty, and rhinoplasty. The most popular non-surgical procedures were botulinum toxin, hyaluronic acid, hair removal, non-surgical skin tightening, and non-surgical fat reduction. All face and head procedures showed notable growth from the previous year, with more than 6.5 million...
PR Newswire
12/06/2024

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in…

Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single point mutation in theHBBgene, which encodes the β subunit of hemoglobin (Hb). Normally, red blood cells adopt a disc-like shape that allows them to move easily through the blood vessels and deliver oxygen throughout the body. In sickle cell disease, red blood cells become crescent or “sickle”-shaped, a dysfunctional state that impairs blood flow, oxygen delivery and triggers...
Nasdaq GlobeNewswire
12/06/2024

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined…

PARIS and CAMBRIDGE, Mass., June12, 2024(GLOBE NEWSWIRE) -- NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST.The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr...
Nasdaq GlobeNewswire
12/06/2024

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; June 12, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date...
Nasdaq GlobeNewswire
12/06/2024

Sanofi: Information concerning the total number of voting rights and shares –…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,599,938 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
12/06/2024

SAFE - First implantations of the Sycamore device in Switzerland

First implantations of the Sycamore device in SwitzerlandFleurieux-sur-l'Arbresle-France – June 12, 2024 at 6 p.m. Safe SA, announces the first implantations of Sycamore devices by Professor Maestretti, at the cantonal hospital of Friborg in Switzerland. The Sycamore implant is a unique implant that allows minimally invasive operations to treat vertebral compression fractures, improve mobility, restore the height of vertebral bodies and reduce back pain (pedicle anchored kyphoplasty)...
Nasdaq GlobeNewswire
12/06/2024
Altri  Comunicati